title: Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.
abstract: The properties of several new, investigational quinolones are reviewed. Desirable characteristics of new quinolones are improved activity against especially Gram-positive bacteria, longer elimination half-life, slower development of resistance, fewer side effects etc. Fleroxacin and lomefloxacin have entered phase III trials: their main advantage lies in improved pharmacokinetics. AM-1091, AT-4140 and T-3262 are still in early phases of development and show improved activity against Gram-positive bacteria. They also show a reduced penetration of the blood-brain barrier, probably resulting in fewer side effects in the central nervous system. AM-1091 shows incomplete cross-resistance with ciprofloxacin.
authors.affiliation: Department of Clinical Pharmacy, Stichting Ziekenzorg Westelijke Mijnstreek, Sittard, the Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Janknegt
authors.forename: Y A
authors.initials: YA
authors.lastname: Hekster
mesh_terms: D042462:4-Quinolones; D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents